Src Family Kinase Oncogenic Potential and Pathways in Prostate Cancer As Revealed by AZD0530

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2008 Aug 6

PMID 18679417

Citations 89

Authors

Y-M Chang

L Bai

S Liu

J C Yang

H-J Kung

C P Evans

Affiliations

Soon will be listed here.

Abstract

Prostate cancer is the most frequently diagnosed cancer in American men. We have previously demonstrated that Src mediates androgen-independent proliferation in prostate cancer. We sought to investigate the Src-mediated oncogenic pathways and tumor biology using AZD0530, a novel Src family kinase/Abl dual-kinase inhibitor that is entering phase II clinical trials. We show that while both Src and Abl are expressed in all prostate cancer cell lines, Src but not Abl is activated in the prostate. Furthermore, Src activation is inhibited by AZD0530 in a rapid and dose-dependent manner. We show that Src mediates cell proliferation in DU145 and PC3 cells at the G1 phase of cell cycle. Src inhibition resulted in decreased binding of beta-catenin to the promoters of G1 phase cell cycle regulators cyclin D1 and c-Myc. C-Myc may also be regulated at the protein level by extracellular signal-regulated kinase 1/2 and GSK3beta. Cell motility factors focal adhesion kinase, p130CAS and paxillin activation in DU145 and PC3 cells were also inhibited. Administration of AZD0530 in mice reduced orthotopic DU145 xenograft growth by 45%. We have further delineated the Src-mediated oncogenic growth and migration pathways in prostate cancer and established mechanistic rationale for Src inhibition as novel therapy in the treatment of prostate cancer.

Citing Articles

HCC-derived CX3CL1 affects hepatocellular carcinoma prognosis and CX3CR1 + MDSC infiltration.

Zhang X, Lou Y, Zheng S, Chang X Eur J Med Res. 2025; 30(1):153.

PMID: 40051011 PMC: 11884201. DOI: 10.1186/s40001-025-02410-z.

KIRA6 is an Effective and Versatile Mast Cell Inhibitor of IgE-mediated Activation.

Wunderle V, Wilhelm T, Boukeileh S, Gossen J, Margreiter M, Sakurov R Eur J Immunol. 2024; 55(2):e202451348.

PMID: 39676406 PMC: 11830387. DOI: 10.1002/eji.202451348.

A high-content microscopy drug screening platform for regulators of the extracellular digestion of lipoprotein aggregates by macrophages.

Ma C, Steinfeld N, Wang W, Maxfield F bioRxiv. 2024; .

PMID: 39605493 PMC: 11601252. DOI: 10.1101/2024.09.26.615160.

The Protective Effects of an Aged Black Garlic Water Extract on the Prostate.

Libero M, Montero-Hidalgo A, Recinella L, Luque R, Generali D, Acquaviva A Nutrients. 2024; 16(17).

PMID: 39275340 PMC: 11396974. DOI: 10.3390/nu16173025.

Dual Drug Repurposing: The Example of Saracatinib.

Ramos R, Vale N Int J Mol Sci. 2024; 25(8).

PMID: 38674150 PMC: 11050334. DOI: 10.3390/ijms25084565.

References

Bang Y, Pirnia F, Fang W, Kang W, Sartor O, Whitesell L . Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci U S A. 1994; 91(12):5330-4. PMC: 43988. DOI: 10.1073/pnas.91.12.5330. View

Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A . Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995; 270(40):23589-97. DOI: 10.1074/jbc.270.40.23589. View

Verras M, Sun Z . Roles and regulation of Wnt signaling and beta-catenin in prostate cancer. Cancer Lett. 2005; 237(1):22-32. DOI: 10.1016/j.canlet.2005.06.004. View

Cronauer M, Schulz W, Ackermann R, Burchardt M . Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines. Int J Oncol. 2005; 26(4):1033-40. DOI: 10.3892/ijo.26.4.1033. View

Zhu S, Bjorge J, Fujita D . PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res. 2007; 67(21):10129-37. DOI: 10.1158/0008-5472.CAN-06-4338. View

Nam S, Buettner R, Turkson J, Kim D, Cheng J, Muehlbeyer S . Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A. 2005; 102(17):5998-6003. PMC: 1087919. DOI: 10.1073/pnas.0409467102. View

Watanabe G, Howe A, Lee R, Albanese C, Shu I, Karnezis A . Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci U S A. 1996; 93(23):12861-6. PMC: 24011. DOI: 10.1073/pnas.93.23.12861. View

Rovin J, Frierson Jr H, Ledinh W, Parsons J, Adams R . Expression of focal adhesion kinase in normal and pathologic human prostate tissues. Prostate. 2002; 53(2):124-32. DOI: 10.1002/pros.10114. View

Parsons J . Focal adhesion kinase: the first ten years. J Cell Sci. 2003; 116(Pt 8):1409-16. DOI: 10.1242/jcs.00373. View

10.

Dong J . Prevalent mutations in prostate cancer. J Cell Biochem. 2005; 97(3):433-47. DOI: 10.1002/jcb.20696. View

11.

Lee L, Louie M, Desai S, Yang J, Chen H, Evans C . Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene. 2004; 23(12):2197-205. DOI: 10.1038/sj.onc.1207344. View

12.

Gray M, Zhang J, Ellis L, Semenza G, Evans D, Watowich S . HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene. 2005; 24(19):3110-20. DOI: 10.1038/sj.onc.1208513. View

13.

Prathapam T, Tegen S, Oskarsson T, Trumpp A, Martin G . Activated Src abrogates the Myc requirement for the G0/G1 transition but not for the G1/S transition. Proc Natl Acad Sci U S A. 2006; 103(8):2695-700. PMC: 1413844. DOI: 10.1073/pnas.0511186103. View

14.

Li G, Qian H . Sensitivity and specificity amplification in signal transduction. Cell Biochem Biophys. 2003; 39(1):45-59. DOI: 10.1385/CBB:39:1:45. View

15.

Gao L, Zhang L, Hu J, Li F, Shao Y, Zhao D . Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res. 2005; 11(17):6333-41. DOI: 10.1158/1078-0432.CCR-05-0148. View

16.

Bromann P, Korkaya H, Courtneidge S . The interplay between Src family kinases and receptor tyrosine kinases. Oncogene. 2004; 23(48):7957-68. DOI: 10.1038/sj.onc.1208079. View

17.

Hennequin L, Allen J, Breed J, Curwen J, Fennell M, Green T . N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006; 49(22):6465-88. DOI: 10.1021/jm060434q. View

18.

Lee L, Guan J, Qiu Y, Kung H . Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol. 2001; 21(24):8385-97. PMC: 100003. DOI: 10.1128/MCB.21.24.8385-8397.2001. View

19.

Unni E, Sun S, Nan B, McPhaul M, Cheskis B, Mancini M . Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res. 2004; 64(19):7156-68. DOI: 10.1158/0008-5472.CAN-04-1121. View

20.

Kotha A, Sekharam M, Cilenti L, Siddiquee K, Khaled A, Zervos A . Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol Cancer Ther. 2006; 5(3):621-9. DOI: 10.1158/1535-7163.MCT-05-0268. View